Latest Ratios: P/E Ratio -0.4x · EV/EBITDA N/A · ROE -20.2%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $69M | $160M | $267M | — | — | — |
| Enterprise Value | $257M | $347M | $266M | — | — | — |
| P/E Ratio → | -0.38 | — | — | — | — | — |
| P/S Ratio | 38.12 | 87.61 | 98.32 | — | — | — |
| P/B Ratio | 0.09 | 0.31 | 104.12 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 190.47 | 97.77 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | -508.8% | -508.8% | -31.0% | 94.0% | 96.0% | 36.5% |
| Operating Margin | -10824.0% | -10824.0% | -123.1% | -43.0% | -71.1% | 2.4% |
| Net Profit Margin | -2867.6% | -2867.6% | -133.0% | -42.9% | -67.1% | 6.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -20.2% | -20.2% | -294.1% | -1186.7% | -776.8% | 54.7% |
| ROA | -14.2% | -14.2% | -151.5% | -158.1% | -364.3% | 33.4% |
| ROIC | -42.1% | -42.1% | -464.5% | -413.5% | -462.6% | — |
| ROCE | -76.2% | -76.2% | -199.4% | -358.5% | -568.0% | 18.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.41 | 0.41 | 0.31 | — | 1.03 | 0.40 |
| Debt / EBITDA | — | — | — | — | — | 0.88 |
| Net Debt / Equity | — | 0.36 | -0.58 | — | 0.54 | 0.06 |
| Net Debt / EBITDA | — | — | — | — | — | 0.12 |
| Debt / FCF | — | — | — | — | — | 0.26 |
| Interest Coverage | -6.40 | -6.40 | -8.19 | -27.96 | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 1.04 | 1.04 | 4.13 | 0.76 | 0.94 | 2.28 |
| Quick Ratio | 1.04 | 1.04 | 4.13 | 0.68 | 0.79 | 1.77 |
| Cash Ratio | 0.10 | 0.10 | 3.75 | 0.65 | 0.57 | 0.80 |
| Asset Turnover | — | 0.00 | 0.74 | 3.43 | 4.00 | 5.59 |
| Inventory Turnover | — | — | 828.47 | 3.58 | 3.07 | 26.59 |
| Days Sales Outstanding | — | 0.56 | 4.95 | 2.71 | 1.17 | 1.96 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.5% | 0.2% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.5% | 0.2% | 0.0% | — | — | — |
| Shares Outstanding | — | $11M | $5M | $6M | $6M | $6M |
Unsustainable capital consumption
According to recent market data, NAKA trades at a P/S multiple of 36.69, which appears disconnected from its 33.04% revenue contraction and suggests that investors are pricing the equity as a speculative option on data assets rather than a functioning clinical services provider with sustainable earning power.
The extreme P/S ratio relative to the company's negative margins indicates that the market is not valuing NAKA on traditional fundamental metrics. Investors should monitor whether the current valuation is supported by the $22.5 million cash position or if the market is misinterpreting the company's potential for a pivot to data licensing.
Based on reported financial statements, NAKA's ROIC has consistently trended in negative territory, reaching -15.2% in 2026Q1, which highlights a persistent inability to generate returns on invested capital that exceed the cost of maintaining its clinical infrastructure and administrative overhead in the Utah market.
The volatility in ROIC, ranging from -167.2% to -2.4% over the last ten quarters, suggests that capital allocation has been highly inefficient. This trend implies that the company is effectively destroying shareholder value with every dollar deployed into its current clinical model, warranting extreme caution regarding future capital expenditures.
As reported in recent SEC filings, NAKA's asset turnover ratio has collapsed to 0.00 in 2026Q1, signaling a near-total breakdown in the company's ability to utilize its asset base to generate revenue compared to its historical performance and broader industry standards for clinical service providers.
The erratic nature of the cash conversion cycle and the lack of meaningful asset turnover suggest that the company's operational processes are not optimized for scale. This inefficiency appears to be a primary driver of the deep operating losses, as the company maintains a fixed-cost base that is not being supported by sufficient patient throughput.
While the P/B ratio of 0.08 might suggest an undervalued asset base, this metric is highly misleading for NAKA because, as indicated in recent financial statements, the book value is heavily inflated by goodwill and intangible assets that lack clear, realizable market value in a distressed scenario.
Investors should focus on the tangible book value or the net cash position rather than the reported P/B ratio, which obscures the reality of the company's eroding equity base. Relying on P/B in this context may lead to a false sense of security regarding the company's underlying asset backing.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NAKA stock.
Nakamoto Inc.'s current P/E ratio is -0.4x. This places it at the 50th percentile of its historical range.
Nakamoto Inc.'s return on equity (ROE) is -20.2%. The historical average is -86.6%.
Based on historical data, Nakamoto Inc. is trading at a P/E of -0.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Nakamoto Inc. has -508.8% gross margin and -10824.0% operating margin.